Ignite Creation Date:
2025-12-24 @ 10:48 PM
Ignite Modification Date:
2025-12-25 @ 8:18 PM
Study NCT ID:
NCT01441869
Status:
COMPLETED
Last Update Posted:
2012-02-08
First Post:
2011-09-26
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Study in Healthy Subjects to Measure Amount of Drug in Blood After Dosing With Different Saxagliptin / Metformin Produc
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'C502994', 'term': 'saxagliptin'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'BASIC_SCIENCE', 'interventionModel': 'CROSSOVER'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 28}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2011-10'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2012-02', 'completionDateStruct': {'date': '2011-12', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2012-02-07', 'studyFirstSubmitDate': '2011-09-26', 'studyFirstSubmitQcDate': '2011-09-26', 'lastUpdatePostDateStruct': {'date': '2012-02-08', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2011-09-28', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2011-12', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'PK Saxagliptin: Observed maximum concentration at steady state (Cmax,ss), time of maximum concentration (tmax,ss) at steady state, and area under the concentration-time curve from zero to the end of the dosing interval at steady state (AUCss)', 'timeFrame': 'At day 5 to day 6 at visit 2 or 3'}, {'measure': 'PK : Metformin Observed maximum concentration at steady state (Cmax,ss), time of maximum concentration (tmax,ss) at steady state, and area under the concentration-time curve from zero to the end of the dosing interval at steady state (AUCss)', 'timeFrame': 'At day 5 to day 6 at visit 2 or 3'}], 'secondaryOutcomes': [{'measure': 'PK : Saxagliptin 5-hydroxy Observed maximum concentration at steady state (Cmax,ss), time of maximum concentration (tmax,ss) at steady state, and area under the concentration-time curve from zero to the end of the dosing interval at steady state (AUCss)', 'timeFrame': 'At day 5 to day 6 at visit 2 or 3'}, {'measure': 'Safety will be assessed by the incidence, severity, and relatedness of adverse events.', 'timeFrame': 'From day -1 visit 2 until performed follow up ( Approximately 30 days)'}]}, 'conditionsModule': {'keywords': ['Phase 1, Healthy male volunteers, pharmacokinetics, saxagliptin/ metformin , Diabex'], 'conditions': ['Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and Metformin']}, 'descriptionModule': {'briefSummary': 'Study in healthy subjects to measure amount of drug in blood after dosing with different saxagliptin / metformin products.', 'detailedDescription': 'Bioequivalence Study of the Fixed-dose Combination of Saxagliptin/Metformin XR Tablets Relative to Saxagliptin (Onglyza� ) Tablets and Australia-sourced Diabex XR Tablets Coadministered to Healthy Subjects in the Fed State During Steady-state Administration'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '55 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Provision of signed and dated informed consent prior to any study specific procedures\n* Males or females aged 18 to 55 years (inclusive) and with a weight of at least 50 kg and a body mass index (BMI) between 18 and 35 kg/m2, inclusive\n* Females must have a negative urine pregnancy test at screening and negative serum pregnancy test on admission to the unit, must not be lactating, and must be using an acceptable method of contraception for at least 1 month before dosing\n* Female volunteers of childbearing potential (including perimenopausal women who have had a menstrual period within 1 year) must be using appropriate birth control (defined as a method which results in a low failure rate, ie, less than 1% per year\n* Oral contraceptive and hormone replacement medications are allowed in this study if used together with a barrier contraceptive method.\n\nExclusion Criteria:\n\n* History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate\n* History or presence of gastrointestinal, hepatic, renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs (except for cholecystectomy)\n* Glomerular filtration rate of less than 60 mL/min (to be estimated at screening only)\n* Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of investigational product (IP)\n* History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the Investigator (eg, seasonal allergies) or history of hypersensitivity to drugs with a similar chemical structure or class to saxagliptin or metformin"}, 'identificationModule': {'nctId': 'NCT01441869', 'briefTitle': 'Study in Healthy Subjects to Measure Amount of Drug in Blood After Dosing With Different Saxagliptin / Metformin Produc', 'organization': {'class': 'INDUSTRY', 'fullName': 'AstraZeneca'}, 'officialTitle': 'Bioequivalence Study of the Fixed-dose Combination of Saxagliptin/Metformin XR Tablets Relative to Saxagliptin (Onglyza� ) Tablets and Australia-sourced Diabex XR Tablets Coadministered to Healthy Subjects in the Fed State During Steady-state Administration', 'orgStudyIdInfo': {'id': 'D1681C00004'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'A', 'description': '5-mg Onglyza (saxagliptin) tablet +1000-mg Diabex extended release tablet', 'interventionNames': ['Drug: Onglyza (saxagliptin)', 'Drug: Diabex']}, {'type': 'EXPERIMENTAL', 'label': 'B', 'description': '5-mg saxagliptin/1000 mg metformin extended release fixed dose combination tablet', 'interventionNames': ['Drug: Onglyza (saxagliptin)', 'Drug: 5-mg saxagliptin/1000 mg metformin']}, {'type': 'EXPERIMENTAL', 'label': 'C', 'description': '5-mg Onglyza (saxagliptin) tablet + 500-mg Diabex extended release tablet', 'interventionNames': ['Drug: Diabex']}, {'type': 'EXPERIMENTAL', 'label': 'D', 'description': '5-mg saxagliptin/500 mg metformin extended release fixed dose combination tablet', 'interventionNames': ['Drug: 5-mg saxagliptin/500 mg metformin']}], 'interventions': [{'name': 'Onglyza (saxagliptin)', 'type': 'DRUG', 'description': 'Oral tablets, 5 mg , single dose', 'armGroupLabels': ['A', 'B']}, {'name': 'Diabex', 'type': 'DRUG', 'description': 'Extended release oral tablets, 1000 mg, single dose', 'armGroupLabels': ['A']}, {'name': '5-mg saxagliptin/1000 mg metformin', 'type': 'DRUG', 'description': 'Extended release fixed dose combination tablet, single dose', 'armGroupLabels': ['B']}, {'name': 'Diabex', 'type': 'DRUG', 'description': 'Extended release oral tablets, 500 mg, single dose', 'armGroupLabels': ['C']}, {'name': '5-mg saxagliptin/500 mg metformin', 'type': 'DRUG', 'description': 'Extended release fixed dose combination tablet, single dose', 'armGroupLabels': ['D']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Overland Park', 'state': 'Kansas', 'country': 'United States', 'facility': 'Research Site', 'geoPoint': {'lat': 38.98223, 'lon': -94.67079}}], 'overallOfficials': [{'name': 'Miriana Kujacic, MD', 'role': 'STUDY_CHAIR', 'affiliation': 'AstraZeneca Mölndal, Sweden'}, {'name': 'Phil Leese, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Quintiles, Inc. Overland Park US'}, {'name': 'Peter Öhman, MD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Astrazeneca, Wilmington, US'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'AstraZeneca', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}